Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (ANEB)
Company Research
Source: Business Wire
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three months ended September 30, 2024, and recent updates.First Quarter Fiscal Year 2025 and Subsequent Highlights:Anebulo announced it has been awarded the first tranche of a two-year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health (“NIH”), under award number 1U01DA059995-01.With the support of NIDA, Anebulo aims to complete IND-enabling activities and the scale up of its intravenous (IV) formulation of selonabant around calendar year end 2024 as it prepares for clinical studies and the Company expects to enroll the first healthy adult volunteer in the first half of calendar 2025.“We are excited to have the
Show less
Read more
Impact Snapshot
Event Time:
ANEB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANEB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANEB alerts
High impacting Anebulo Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANEB
News
- Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.MarketBeat
- Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates [Yahoo! Finance]Yahoo! Finance
- Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $8.00 price target on the stock.MarketBeat
- Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent UpdatesBusiness Wire
- Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
ANEB
Earnings
- 5/15/24 - Beat
ANEB
Sec Filings
- 12/10/24 - Form 4
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- ANEB's page on the SEC website